Erasca (ERAS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Apr, 2026Executive summary
The annual meeting will be held virtually on June 26, 2026, with voting available online, by phone, or by mail for shareholders of record as of April 27, 2026.
Shareholders will vote on electing three Class II directors, ratifying the appointment of KPMG LLP as independent auditor for 2026, and any other business that may arise.
The company emphasizes electronic delivery of proxy materials to reduce costs and environmental impact.
Voting matters and shareholder proposals
Proposal 1: Elect Alexander W. Casdin, Julie Hambleton, M.D., and Michael D. Varney, Ph.D. as Class II directors for a three-year term expiring at the 2029 annual meeting.
Proposal 2: Ratify KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Shareholders may submit proposals for the 2027 annual meeting by January 15, 2027, and must comply with SEC and bylaw requirements.
Board of directors and corporate governance
The board consists of eight members, with a majority deemed independent under Nasdaq rules.
The board is divided into three classes with staggered three-year terms; directors may only be removed for cause by a two-thirds shareholder vote.
The board has Audit, Compensation, and Nominating and Corporate Governance Committees, all composed of independent directors.
The Lead Independent Director role was established for enhanced oversight, currently held by Dr. Bristol.
The board conducts periodic self-evaluations and encourages director attendance at annual meetings.
Latest events from Erasca
- Early clinical milestones, extended cash runway, and strong preclinical data drive optimism.ERAS
BofA Securities 2025 Healthcare Conference9 Jul 2026 - Promising RAS/MAPK-targeted therapies advance with strong data and key milestones ahead.ERAS
43rd Annual J.P. Morgan Healthcare Conference 20258 Jul 2026 - Naporafenib plus trametinib shows strong efficacy in NRAS-mutant melanoma; RAS franchise advances to IND in 2025.ERAS
R&D Update8 Jul 2026 - ERAS-0015 shows high potency and safety at low doses, with broad development and combination plans.ERAS
Guggenheim Securities Emerging Outlook: Biotech Summit 20268 Jul 2026 - Lead RAS-targeting agents show high NSCLC response rates and favorable safety, with key updates ahead.ERAS
Jefferies Global Healthcare Conference 20263 Jun 2026 - Promising efficacy and safety for pan-RAS inhibitor, with pivotal trials and combos advancing.ERAS
Bank of America Global Healthcare Conference 202613 May 2026 - Q1 2026 net loss hit $183.4M on license expense; cash runway extends into H2 2028.ERAS
Q1 202611 May 2026 - Leading RAS/MAPK-targeted therapies show strong preclinical and early clinical promise.ERAS
Corporate presentation1 May 2026 - Virtual meeting to elect directors and ratify auditor, with board support for all proposals.ERAS
Proxy filing28 Apr 2026